What is aleniglipron?
Aleniglipron is an investigational orally-available, small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor being developed by Structure Therapeutics for the treatment of obesity.
Yanuki
ARTICLE DETAIL
New Oral GLP-1 Agonist Shows Promise in Obesity Treatment | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries | New Oral GLP-1 Agonist Shows Promise in Obesity Treatment | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries
Health / Nutrition
New Oral GLP-1 Agonist Shows Promise in Obesity Treatment
Structure Therapeutics has announced positive topline data from its ACCESS program for aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist. The studies show promising results in weight loss for individuals with obesity or...
Key Insights
- Aleniglipron achieved a placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at the 120 mg dose in the Phase 2b ACCESS study.
- The exploratory ACCESS II study showed a placebo-adjusted mean weight loss of up to 15.3% (35.5 lbs) with the 240 mg dose.
- A lower starting dose of 2.5 mg in the Body Composition Study improved tolerability, with no adverse event-related treatment discontinuations.
- Data supports advancement to Phase 3 clinical development planned for mid-2026.
In-Depth Analysis
Aleniglipron (GSBR-1290) is an investigational orally-available, small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor. The ACCESS clinical program included the Phase 2b ACCESS study, the ACCESS II study, the Body Composition study, and the ACCESS open label extension (OLE) study.
**Phase 2b ACCESS Study:** Participants achieved statistically significant weight loss with various doses. At Week 36, 86% of participants in the 120 mg dose cohort achieved at least 5% weight loss, and 70% achieved at least 10% weight loss. Improvements in systolic blood pressure and HbA1c were also noted.
**ACCESS II Study:** Higher doses of aleniglipron led to significant weight loss. The placebo-adjusted mean percent change in body weight at 36 weeks was -15.3% with the 240 mg dose.
**Body Composition Study:** Starting with a lower dose of 2.5 mg improved tolerability.
**ACCESS Open-Label Extension Study:** Showed continuing weight loss in all dose cohorts out to 44 weeks, with no evidence of a weight loss plateau.
The company plans to request a meeting with the FDA in the first half of 2026 to finalize the Phase 3 design and intends to initiate the Phase 3 program by mid-2026.
FAQ
What were the main findings of the ACCESS clinical program?
The ACCESS program demonstrated clinically meaningful and statistically significant weight loss, with good tolerability, supporting advancement to Phase 3 clinical development.
Takeaways
- Aleniglipron shows promise as an oral treatment option for obesity, potentially expanding access to treatment.
- The drug demonstrated significant weight loss and a favorable safety profile in clinical trials.
- Phase 3 development is planned for mid-2026, which could bring this therapy closer to market.
Discussion
Do you think this oral treatment will significantly impact the obesity epidemic? Let us know in the comments!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.